Zareifar Soheila, Shakibazad Nader, Zekavat Omid Reza, Bordbar Mohammadreza, Shahriari Mahdi
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Pediatric Hematology and Oncology, Bushehr University of Medical Sciences, Bushehr, Iran.
J Oncol Pharm Pract. 2020 Mar;26(2):481-486. doi: 10.1177/1078155219852670. Epub 2019 Jun 2.
Neuroblastoma commonly required multimodal therapy containing surgery, chemotherapy, radiotherapy, and immunotherapy.
In our case, who had refractory metastatic neuroblastoma, we use histone deacetylase inhibitor (panobinostat) in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine (MIBG) therapy.
This approach leads to successfully treat the patient. MIBG scan and bone marrow examination after therapy revealed no evidence of tumor. Now, she underwent autologous transplantation six months ago and free of tumor.
Panobinostat can cause apoptosis induction in refractory metastatic neuroblastoma in combination with MIBG therapy and chemotherapy.
神经母细胞瘤通常需要包含手术、化疗、放疗和免疫疗法的多模式治疗。
在我们的病例中，患者患有难治性转移性神经母细胞瘤，我们使用组蛋白去乙酰化酶抑制剂（帕比司他）联合化疗药物及碘-131-间碘苄胍（MIBG）治疗。
这种方法成功治愈了该患者。治疗后的MIBG扫描和骨髓检查未发现肿瘤迹象。现在，她六个月前接受了自体移植，目前无肿瘤。
帕比司他联合MIBG治疗和化疗可诱导难治性转移性神经母细胞瘤凋亡。
